EUVIMEDScopri EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib

Hana Dostálová, Vladimír Kryštof iD

Hematological Oncology · 2024

DOI: 10.1002/hon.3294 ↗

At a glance

Übersichtsarbeit in Hematological Oncology, 2024. Written by Hana Dostálová and 1 co-authors. Institution: Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Olomouc, Czech Republic. Major MEDLINE topics: Agammaglobulinaemia Tyrosine Kinase, Drug Resistance, Neoplasm, Pyrazoles, Pyrimidines. Cited 7 times so far (Crossref); 87 references. The full text is freely available (open access, CC BY 4.0). Funded by: Univerzita Palackého v Olomouci, Grantová Agentura České Republiky.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Bruton's tyrosine kinase (BTK) inhibitors have revolutionized the treatment of B‐cell malignancies. They target BTK, a key effector in the B‐cell receptor (BCR) signaling pathway, crucial for B‐cell survival and proliferation. The first‐in‐class irreversible BTK inhibitor, ibrutinib, was approved for various B‐cell malignancies but has limitations due to off‐target effects. Second‐generation inhibitors, such as acalabrutinib and zanubrutinib, offer improved selectivity and reduced side effects. However, resistance to BTK inhibitors, driven by BTK mutations, remains a challenge. Combinatorial therapies with PI3K inhibitors, immune checkpoint inhibitors, BH3 mimetics, and anti‐CD20 antibodies show promise in overcoming resistance. Noncovalent BTK inhibitors and proteolysis‐targeting chimeras (PROTACs) are emerging strategies with potential to combat resistance. Overall, advancements in BTK‐targeted therapies provide hope for improved outcomes in patients with B‐cell malignancies and a promising avenue to address drug resistance. Further research is needed to optimize combination therapies and identify optimal treatment regimens.

Subjects

MeSH terms (MEDLINE)

Agammaglobulinaemia Tyrosine KinaseDrug Resistance, NeoplasmPyrazolesPyrimidinesProtein Kinase InhibitorsPiperidinesHumansLymphoma, B-CellTyrosine Kinase Inhibitors

Author keywords

BTKinhibitorresistancezanubrutinib

Substances

Agammaglobulinaemia Tyrosine KinasezanubrutinibPyrazolesPyrimidinesProtein Kinase InhibitorsPiperidinesBTK protein, humanTyrosine Kinase Inhibitors

Authors and institutions

  • Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Olomouc, Czech Republic.

ORCID profiles: Vladimír Kryštof

Funding

  • Univerzita Palackého v Olomouci
  • Grantová Agentura České Republiky

Cite

APA

Dostálová, H., & Kryštof, V. (2024). Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib. Hematological Oncology. https://doi.org/10.1002/hon.3294

Vancouver

Dostálová H, Kryštof V. Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib. Hematological Oncology. 2024. doi:10.1002/hon.3294

BibTeX
@article{Dostlov2024,
  author = {Dostálová, Hana and Kryštof, Vladimír},
  title = {Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib},
  journal = {Hematological Oncology},
  year = {2024},
  doi = {10.1002/hon.3294}
}
Start for free →